Flem­ming Ørn­skov takes on a new chal­lenge, dri­ving a $10B der­ma­tol­ogy spin­out with some big plans for growth

Just as Gal­der­ma was be­ing spun out of Nestlé with plans to be­come the biggest in­de­pen­dent der­ma­tol­ogy com­pa­ny on the plan­et, they signed a new, high pro­file CEO and CFO who have built their rep­u­ta­tions around dri­ving growth at Shire, set­ting the stage for a $62 bil­lion Take­da buy­out.

Thomas Dit­trich

Flem­ming Orn­skov and Thomas Dit­trich, who shook up Shire — hard — to make it in­to a top play­er in rare dis­eases and oph­thal­mol­o­gy, took the two top spots at Gal­der­ma, which of­fi­cial­ly re­brand­ed from Nestlé Skin Health a week ago fol­low­ing a 10.2 bil­lion CHF deal.

Stu­art Raet­z­man, Nestlé Skin Health’s CEO for the past 3 years, switched to a di­rec­tor’s role.

Orn­skov had this to say about his new post:

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER